XML 34 R52.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Collaboration Revenue - Additional Information (Details) (USD $) | 3 Months Ended | 0 Months Ended | 1 Months Ended | 0 Months Ended
--- | --- | --- | --- | ---
Mar. 31, 2015 | Mar. 31, 2014 | Jun. 05, 2012 | Sep. 30, 2013 | Apr. 30, 2013 | Oct. 05, 2012 | Mar. 29, 2013 | Feb. 14, 2013 | Mar. 26, 2014 | Jan. 06, 2011 | Dec. 18, 2013 | Dec. 31, 2014 | Mar. 31, 2014 | Jan. 10, 2014 | Jun. 28, 2013 | Oct. 24, 2012
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue | $ 14,735,000 xon_CollaborationRevenues | $ 7,837,000 xon_CollaborationRevenues |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue | 111,287,000 us-gaap_DeferredRevenue |  |  |  |  |  |  |  |  |  |  | 113,209,000 us-gaap_DeferredRevenue |  |  |  |
Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue | 3,031,000 xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember | 1,882,000 xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue | 104,297,000 us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember |  |  |  |  |  |  |  |  |  |  | 107,228,000 us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember |  |  |  |
Oragenics ECC 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percent of shares outstanding at the date of achievement of future milestone |  |  | 1.00%xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingShares / us-gaap_TypeOfArrangementAxis = xon_OragenicsEccMember |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty rate as a percentage of net profit |  |  | 25.00%xon_CollaborativeArrangementRoyaltyRateAsPercentageOfNetProfit / us-gaap_TypeOfArrangementAxis = xon_OragenicsEccMember |  |  |  |  |  |  |  |  |  |  |  |  |
Required notice period for voluntary termination of collaborative agreement |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of shares outstanding at the date of achievement of future milestone 2 |  |  | 1.50%xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesTwo / us-gaap_TypeOfArrangementAxis = xon_OragenicsEccMember |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of shares outstanding at the date of achievement of future milestone 3 |  |  | 2.00%xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesThree / us-gaap_TypeOfArrangementAxis = xon_OragenicsEccMember |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of shares outstanding at the date of achievement of future milestone 4 |  |  | 2.50%xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesFour / us-gaap_TypeOfArrangementAxis = xon_OragenicsEccMember |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of shares outstanding at the date of achievement of future milestone 5 |  |  | 3.00%xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesFive / us-gaap_TypeOfArrangementAxis = xon_OragenicsEccMember |  |  |  |  |  |  |  |  |  |  |  |  |
Oragenics ECC 1 | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue | 5,033,000 us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_OragenicsEccMember |  |  |  |  |  |  |  |  |  |  | 5,171,000 us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_OragenicsEccMember |  |  |  |
Oragenics ECC 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Required notice period for voluntary termination of collaborative agreement |  |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |
Consideration to be received upon achievement of future milestone 1 |  | 2,000,000 xon_FutureMilestonePaymentOne / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember |  |  |  |  |  |  |  |  |  |  | 2,000,000 xon_FutureMilestonePaymentOne / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember |  |  |
Consideration to be received upon achievement of future milestone 2 |  | 5,000,000 xon_FutureMilestonePaymentTwo / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember |  |  |  |  |  |  |  |  |  |  | 5,000,000 xon_FutureMilestonePaymentTwo / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember |  |  |
Consideration to be received upon achievement of future milestone 3 |  | 10,000,000 xon_FutureMilestonePaymentThree / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember |  |  |  |  |  |  |  |  |  |  | 10,000,000 xon_FutureMilestonePaymentThree / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember |  |  |
Royalty rate as a percentage of net sales, tier 1 |  |  |  | 10.00%xon_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember |  |  |  |  |  |  |  |  |  |  |  |
Oragenics ECC 2 | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue | 4,715,000 us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember |  |  |  |  |  |  |  |  |  |  | 4,839,000 us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember |  |  |  |
Fibrocell Science, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue | 2,161,000 xon_CollaborationRevenues / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember | 1,310,000 xon_CollaborationRevenues / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember |  |  |  |  |  |  |  |  |  |  |  |  |  |
Required notice period for voluntary termination of collaborative agreement |  |  |  |  |  | 90 days |  |  |  |  |  |  |  |  |  |
Royalty rate as a percentage of net sales, tier 1 |  |  |  |  |  | 7.00%xon_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember |  |  |  |  |  |  |  |  |  |
Reverse stock split ratio |  |  |  |  | 1-for-25 |  |  |  |  |  |  |  |  |  |  |
Level of net sales at which royalty rate changes to tier 2 |  |  |  |  |  | 25,000,000 xon_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember |  |  |  |  |  |  |  |  |  |
Royalty rate as a percentage of net sales, tier 2 |  |  |  |  |  | 14.00%xon_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember |  |  |  |  |  |  |  |  |  |
Royalty rate of savings from improvement |  |  |  |  |  | 33.00%xon_CollaborativeArrangementRoyaltyRateAsPercentageOfSavingsFromImprovement / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember |  |  |  |  |  |  |  |  |  |
Fibrocell Science, Inc. | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue | 448,000 xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember | 448,000 xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue | 17,043,000 us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember |  |  |  |  |  |  |  |  |  |  | 17,491,000 us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember |  |  |  |
Genopaver, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue | 669,000 xon_CollaborationRevenues / us-gaap_TypeOfArrangementAxis = xon_GenopaverEccMember | 490,000 xon_CollaborationRevenues / us-gaap_TypeOfArrangementAxis = xon_GenopaverEccMember |  |  |  |  |  |  |  |  |  |  |  |  |  |
Required notice period for voluntary termination of collaborative agreement |  |  |  |  |  |  | 90 days |  |  |  |  |  |  |  |  |
Genopaver, LLC | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue | 69,000 xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_GenopaverEccMember | 69,000 xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_GenopaverEccMember |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue | 2,454,000 us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_GenopaverEccMember |  |  |  |  |  |  |  |  |  |  | 2,523,000 us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_GenopaverEccMember |  |  |  |
AquaBounty Technologies, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty rate as a percentage of gross profit |  |  |  |  |  |  |  | 16.66%xon_CollaborativeArrangementRoyaltyRateAsPercentageOfGrossProfit / us-gaap_TypeOfArrangementAxis = xon_AquaBountyMember |  |  |  |  |  |  |  |
Intrexon Energy Partners, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue | 2,810,000 xon_CollaborationRevenues / us-gaap_TypeOfArrangementAxis = xon_IntrexonEnergyPartnersMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Required notice period for voluntary termination of collaborative agreement |  |  |  |  |  |  |  |  | 90 days |  |  |  |  |  |  |
Intrexon Energy Partners, LLC | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue | 625,000 xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_IntrexonEnergyPartnersMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue | 22,500,000 us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_IntrexonEnergyPartnersMember |  |  |  |  |  |  |  |  |  |  | 23,125,000 us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_IntrexonEnergyPartnersMember |  |  |  |
ZIOPHARM Oncology, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue | 3,801,000 xon_CollaborationRevenues / us-gaap_TypeOfArrangementAxis = xon_ZiopharmMember | 2,680,000 xon_CollaborationRevenues / us-gaap_TypeOfArrangementAxis = xon_ZiopharmMember |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percent of shares outstanding at the date of achievement of future milestone |  |  |  |  |  |  |  |  |  | 7.495%xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingShares / us-gaap_TypeOfArrangementAxis = xon_ZiopharmMember |  |  |  |  |  |
Royalty rate as a percentage of net profit |  |  |  |  |  |  |  |  |  | 50.00%xon_CollaborativeArrangementRoyaltyRateAsPercentageOfNetProfit / us-gaap_TypeOfArrangementAxis = xon_ZiopharmMember |  |  |  |  |  |
Required notice period for voluntary termination of collaborative agreement |  |  |  |  |  |  |  |  |  | 90 days |  |  |  |  |  |
ZIOPHARM Oncology, Inc. | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue | 644,000 xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_ZiopharmMember | 644,000 xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_ZiopharmMember |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue | 22,549,000 us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_ZiopharmMember |  |  |  |  |  |  |  |  |  |  | 23,193,000 us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_ZiopharmMember |  |  |  |
S & I Ophthalmic, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue | 755,000 xon_CollaborationRevenues / us-gaap_TypeOfArrangementAxis = xon_SIOphthalmicMember | 879,000 xon_CollaborationRevenues / us-gaap_TypeOfArrangementAxis = xon_SIOphthalmicMember |  |  |  |  |  |  |  |  |  |  |  |  |  |
Required notice period for voluntary termination of collaborative agreement |  |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |
S & I Ophthalmic, LLC | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue | 0 xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_SIOphthalmicMember | 0 xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_SIOphthalmicMember |  |  |  |  |  |  |  |  |  |  |  |  |  |
OvaXon, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue | 644,000 xon_CollaborationRevenues / us-gaap_TypeOfArrangementAxis = xon_OvaXonMember | 169,000 xon_CollaborationRevenues / us-gaap_TypeOfArrangementAxis = xon_OvaXonMember |  |  |  |  |  |  |  |  |  |  |  |  |  |
Required notice period for voluntary termination of collaborative agreement |  |  |  |  |  |  |  |  |  |  | 90 days |  |  |  |  |
OvaXon, LLC | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue | 0 xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_OvaXonMember | 0 xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_OvaXonMember |  |  |  |  |  |  |  |  |  |  |  |  |  |
Persea Bio, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue | 240,000 xon_CollaborationRevenues / us-gaap_TypeOfArrangementAxis = xon_PerseaBioLLCMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Required notice period for voluntary termination of collaborative agreement |  |  |  |  |  |  |  |  |  |  |  | 90 days |  |  |  |
Persea Bio, LLC | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue | 125,000 xon_CollaborationRevenues / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_PerseaBioLLCMember |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue | 4,875,000 us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_PerseaBioLLCMember |  |  |  |  |  |  |  |  |  |  | 5,000,000 us-gaap_DeferredRevenue / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_PerseaBioLLCMember |  |  |  |
Upfront | Oragenics ECC 1 | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement consideration received, shares |  |  | 4,392,425 xon_CollaborativeArrangementConsiderationReceivedShares / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_OragenicsEccMember |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement consideration received, value |  |  | 6,588,000 xon_CollaborativeArrangementConsiderationReceivedValue / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_OragenicsEccMember |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront | Oragenics ECC 2 | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement consideration received, shares |  |  |  | 1,348,000 xon_CollaborativeArrangementConsiderationReceivedShares / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement consideration received, value |  |  |  | 3,503,000 xon_CollaborativeArrangementConsiderationReceivedValue / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement consideration received, value of convertible promissory note |  |  |  | 1,956,000 xon_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember |  |  |  |  |  |  |  |  |  |  |  |
Conversion of promissory note into Common stock |  |  |  |  |  |  |  |  |  |  | 698,241 us-gaap_DebtConversionConvertedInstrumentSharesIssued1 / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_OragenicsSecondEccMember |  |  |  |  |
Upfront | Fibrocell Science, Inc. | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement consideration received, shares |  |  |  |  |  | 1,317,520 xon_CollaborativeArrangementConsiderationReceivedShares / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember |  |  |  |  |  |  |  |  |  |
Collaborative arrangement consideration received, value |  |  |  |  |  | 7,576,000 xon_CollaborativeArrangementConsiderationReceivedValue / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember |  |  |  |  |  |  |  |  |  |
Upfront | Genopaver, LLC | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement consideration received, value |  |  |  |  |  |  | 3,000,000 xon_CollaborativeArrangementConsiderationReceivedValue / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_GenopaverEccMember |  |  |  |  |  |  |  |  |
Upfront | Intrexon Energy Partners, LLC | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement consideration received, value |  |  |  |  |  |  |  |  | 25,000,000 xon_CollaborativeArrangementConsiderationReceivedValue / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_IntrexonEnergyPartnersMember |  |  |  | 25,000,000 xon_CollaborativeArrangementConsiderationReceivedValue / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_IntrexonEnergyPartnersMember |  |  |
Upfront | ZIOPHARM Oncology, Inc. | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement consideration received, shares |  |  |  |  |  |  |  |  |  | 3,636,926 xon_CollaborativeArrangementConsiderationReceivedShares / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_ZiopharmMember |  |  |  |  |  |
Collaborative arrangement consideration received, value |  |  |  |  |  |  |  |  |  | 17,457,000 xon_CollaborativeArrangementConsiderationReceivedValue / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_ZiopharmMember |  |  |  |  |  |
Upfront | Ziopharm Oncology ECC Separate Unit of Accounting | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  | 1,115,000 xon_CollaborationRevenues / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_ZiopharmOncologyEccSeparateUnitOfAccountingMember |  |  |  |  |  |
Upfront | Ziopharm Oncology ECC Unit of Accounting One | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  | 16,342,000 us-gaap_DeferredRevenue / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_ZiopharmOncologyEccUnitOfAccountingOneMember |  |  |  |  |  |
Upfront | Persea Bio, LLC | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement consideration received, value |  |  |  |  |  |  |  |  |  |  |  | 5,000,000 xon_CollaborativeArrangementConsiderationReceivedValue / us-gaap_ContingentConsiderationByTypeAxis = xon_UpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_PerseaBioLLCMember |  |  |  |
Supplemental Upfront | Fibrocell Science, Inc. | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement consideration received, shares |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,024,590 xon_CollaborativeArrangementConsiderationReceivedShares / us-gaap_ContingentConsiderationByTypeAxis = xon_SupplementalUpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember | 1,243,781 xon_CollaborativeArrangementConsiderationReceivedShares / us-gaap_ContingentConsiderationByTypeAxis = xon_SupplementalUpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember |
Collaborative arrangement consideration received, value |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,225,000 xon_CollaborativeArrangementConsiderationReceivedValue / us-gaap_ContingentConsiderationByTypeAxis = xon_SupplementalUpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember | 7,612,000 xon_CollaborativeArrangementConsiderationReceivedValue / us-gaap_ContingentConsiderationByTypeAxis = xon_SupplementalUpfrontMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_FibrocellMember |
Milestone One | ZIOPHARM Oncology, Inc. | Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement consideration received, shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,636,926 xon_CollaborativeArrangementConsiderationReceivedShares / us-gaap_ContingentConsiderationByTypeAxis = xon_MilestoneOneMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_ZiopharmMember
Collaborative arrangement consideration received, value |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 18,330,000 xon_CollaborativeArrangementConsiderationReceivedValue / us-gaap_ContingentConsiderationByTypeAxis = xon_MilestoneOneMember / us-gaap_ProductOrServiceAxis = xon_UpfrontAndMilestonePaymentsMember / us-gaap_TypeOfArrangementAxis = xon_ZiopharmMember

X
- Definition The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586 + Details
Name: | us-gaap_DebtConversionConvertedInstrumentSharesIssued1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section C + Details
Name: | us-gaap_StockholdersEquityReverseStockSplit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | xon_CollaborationAgreementsLineItems
Namespace Prefix: | xon_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Notice period required for voluntary termination of collaboration. + References No definition available. + Details
Name: | xon_CollaborationAgreementTerminationNoticePeriod
Namespace Prefix: | xon_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue from contractual agreements with collaborators whereby the collaborators obtain exclusive access to the entity's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Includes revenue recognized from upfront payments received upon consummation of the agreement, reimbursements for costs incurred by the entity for research and development efforts, and milestone payments received upon achievement of specified development, regulatory and commercial activities as defined in the collaboration agreements. + References No definition available. + Details
Name: | xon_CollaborationRevenues
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of shares outstanding of collaborator to which the entity is entitled upon achievement of future milestone. + References No definition available. + Details
Name: | xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingShares
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of shares outstanding of collaborator to which the entity is entitled upon achievement of future milestone 5. + References No definition available. + Details
Name: | xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesFive
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of shares outstanding of collaborator to which the entity is entitled upon achievement of future milestone 4. + References No definition available. + Details
Name: | xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesFour
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of shares outstanding of collaborator to which the entity is entitled upon achievement of future milestone 3. + References No definition available. + Details
Name: | xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesThree
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of shares outstanding of collaborator to which the entity is entitled upon achievement of future milestone 2. + References No definition available. + Details
Name: | xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesTwo
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of shares of common stock of a collaborator received by the entity as consideration + References No definition available. + Details
Name: | xon_CollaborativeArrangementConsiderationReceivedShares
Namespace Prefix: | xon_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value of consideration received by the entity for collaboration + References No definition available. + Details
Name: | xon_CollaborativeArrangementConsiderationReceivedValue
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Value of promissory note received as consideration of collaboration agreement which can be settled in cash or common stock. + References No definition available. + Details
Name: | xon_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Level of net sales, as defined in the collaboration agreement, at which the royalty rate changes to tier 2. + References No definition available. + Details
Name: | xon_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Percentage of net sales, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled, tier 1. + References No definition available. + Details
Name: | xon_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of net sales, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled, tier 2. + References No definition available. + Details
Name: | xon_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of gross profit, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled. + References No definition available. + Details
Name: | xon_CollaborativeArrangementRoyaltyRateAsPercentageOfGrossProfit
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of net profit, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled. + References No definition available. + Details
Name: | xon_CollaborativeArrangementRoyaltyRateAsPercentageOfNetProfit
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of cost of goods sold, as defined in the collaboration agreement, savings generated by production improvements used to calculate royalty payments to which the entity is entitled. + References No definition available. + Details
Name: | xon_CollaborativeArrangementRoyaltyRateAsPercentageOfSavingsFromImprovement
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value of consideration to be received from the collaborator upon achievement of milestone 1. + References No definition available. + Details
Name: | xon_FutureMilestonePaymentOne
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Value of consideration to be received from the collaborator upon achievement of milestone 3. + References No definition available. + Details
Name: | xon_FutureMilestonePaymentThree
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Value of consideration to be received from the collaborator upon achievement of milestone 2. + References No definition available. + Details
Name: | xon_FutureMilestonePaymentTwo
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=xon_MilestoneOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=xon_SupplementalUpfrontMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=xon_UpfrontMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=xon_UpfrontAndMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_AquaBountyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_FibrocellMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_GenopaverEccMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_IntrexonEnergyPartnersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_OragenicsEccMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_OragenicsSecondEccMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_OvaXonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_PerseaBioLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_SIOphthalmicMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_ZiopharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |